title: New therapies for diabetes.
abstract: The role of hormones secreted by the gut in maintaining blood glucose homeostasis has recently been recognized. This recognition has led to the emergence of several novel classes of medications--the glucagon-like peptide-1 (GLP-1) agonists and the dipeptidyl peptidase (DPP)-IV inhibitors--that may target a key element of the underlying pathophysiology of type 2 diabetes mellitus (DM). Both GLP-1 agonists and DPP-IV inhibitors may have the ability to expand beta-cell mass. Because the demise of beta-cell mass and function is a critical element in the progression of type 2 DM, these agents may have the potential to reverse the natural history of type 2 DM. However, further studies are needed to confirm both long-term beta-cell preservation and the role of these agents in the management of diabetes.
authors: Division of Endocrinology, Mount Sinai School of Medicine, New York, New York 10029, USA. dina.green@mountsinai.org
authors: Dina E
authors: DE
authors: Green
mesh_terms: D000682:Amyloid / Q000627:therapeutic use; D001786:Blood Glucose / Q000187:drug effects; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D004152:Dipeptidyl-Peptidases and Tripeptidyl-Peptidases / Q000037:antagonists & inhibitors*; D018450:Disease Progression; D000077270:Exenatide; D052216:Glucagon-Like Peptide 1 / Q000031:analogs & derivatives / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D058228:Islet Amyloid Polypeptide; D000069450:Liraglutide; D010455:Peptides / Q000627:therapeutic use; D014688:Venoms / Q000627:therapeutic use
chemical_list: D000682:Amyloid; D001786:Blood Glucose; D007004:Hypoglycemic Agents; D058228:Islet Amyloid Polypeptide; D010455:Peptides; D014688:Venoms; D000069450:Liraglutide; D052216:Glucagon-Like Peptide 1; D000077270:Exenatide; C105254:pramlintide; D004152:Dipeptidyl-Peptidases and Tripeptidyl-Peptidases